By Fineline Cube China’s National Medical Products Administration (NMPA) has released the “2026 Adjustment Work Plan for the National Reimbursement Drug Lists for Basic Medical Insurance, Maternity Insurance, Work-Related Injury Insurance, and the Commercial Health Insurance Innovative Drug List,” opening the online application system from June 1–10, 2026. The comprehensive framework establishes detailed eligibility criteria for both new drug inclusion and existing drug renewal, while introducing stringent price warning mechanisms to control healthcare costs in the world’s second-largest pharmaceutical market.
Regulatory Framework
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Program | National Reimbursement Drug Lists (NRDL) 2026 Adjustment |
| Application Window | June 1–10, 2026 |
| Key Components | Basic Medical Insurance, Maternity Insurance, Work-Related Injury Insurance, Commercial Health Insurance Innovative Drug List |
| Price Control Mechanism | Yellow/Red label warnings based on reimbursement standard multiples |
| Implementation Timeline | Drugs must complete technical review by June 10, 2026; marketing approval required by July 3, 2026 |
Eligibility Criteria for New Drug Inclusion
The 2026 adjustment plan defines eight distinct pathways for out-of-list drugs to qualify for NRDL inclusion:
- New generic name drugs approved or completing technical review between January 1, 2021 – June 10, 2026
- Significant indication changes for drugs approved during the same period with updated drug approval certificates
- Conditional-to-regular approvals for new generic name drugs granted conditional approval after January 1, 2020, and converted to regular approval between January 1, 2023 – May 31, 2026
- National Essential Medicines List inclusions
- Commercial Health Insurance Innovative Drug List (2025) inclusions
- Encouraged Generic Drugs or Pediatric R&D Priority Drugs approved before June 10, 2026
- Rare disease treatments approved or completing technical review before June 10, 2026
- Previously negotiated drugs that lost coverage due to unsuccessful renewal, with new generic equivalents approved between January 1, 2021 – May 31, 2026
Notably, drugs failing to complete technical review by June 10 but obtaining marketing approval before July 3 do not qualify for the 2026 cycle.
Renewal Requirements for Existing Drugs
For drugs currently on the list seeking renewal or scope adjustment:
- Standard renewals: Negotiated drugs with agreements expiring December 31, 2026, maintaining current indications
- Voluntary scope adjustments: Same cohort of drugs seeking alignment between approved indications and reimbursement scope
- Indication expansion renewals: Drugs with significant indication changes approved between January 1, 2021 – June 10, 2026
Pricing and Bidding Regulations
The 2026 framework introduces enhanced price transparency and control measures:
- Price undertaking requirement: Companies must guarantee that institutional supply prices during the bidding validity period will not exceed quoted bid prices
- Yellow label warning: Triggered when listed online prices exceed reimbursement standards by 1.8 times
- Red label warning: Activated when listed online prices exceed reimbursement standards by 3 times
- Procurement independence: Bidding participation does not preclude inclusion in national centralized volume-based procurement or government pricing programs
Strategic Market Implications
The revised NRDL process reflects China’s dual objectives of expanding patient access to innovative therapies while controlling healthcare expenditure growth. Pharmaceutical companies face critical strategic decisions:
- Timeline compression: The narrow June 1–10 application window requires immediate preparation
- Dual-listing opportunities: Exclusive drugs meeting criteria ① or ⑦ may apply for commercial insurance list inclusion only, or pursue both commercial and basic reimbursement lists
- Price discipline: The yellow/red warning system creates strong incentives for competitive pricing, potentially accelerating price erosion in the Chinese market
“China’s NRDL remains the most significant market access opportunity for global pharmaceutical companies,” said Li Mei, healthcare policy analyst at Dragon Capital. “However, the 2026 framework demonstrates increasingly sophisticated cost-control mechanisms that will require careful pricing strategy and robust health economics data.”
Industry estimates suggest the 2026 NRDL adjustment could add 80–100 new drugs to China’s reimbursement system, representing potential annual sales of ¥30–40 billion ($4.2–5.6 billion) across all therapeutic areas.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory processes, market access opportunities, and pricing dynamics in China’s pharmaceutical market. Actual outcomes may vary based on final NRDL decisions, company bidding strategies, and evolving healthcare policy priorities.-Fineline Info & Tech